Peter Teuber, Ph.D. (President) has more than 20 years of experience in the pharmaceutical industry and a proven track record of developing successful specialty pharmaceuticals (Xeloda®, Angiomax®).

The business model of Orphan Therapeutics, LLC is to license niche products currently unavailable in the USA, but with proven efficacy for high medical need indications from primarily European based companies and develop those for FDA approval under Orphan Drug protection. To develop such products efficiently, it is essential to keep the internal infrastructure at a minimum by leveraging strategic partnerships with other experienced independent pharmaceutical executives and organizations (virtual company concept), including the out-licensing of marketing and sales efforts post-approval.